<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00966485</url>
  </required_header>
  <id_info>
    <org_study_id>84-2230</org_study_id>
    <nct_id>NCT00966485</nct_id>
  </id_info>
  <brief_title>Dose-related Effect of Aspirin on Laboratory-defined Acetylsalicylic Acid Resistance and Clinical Outcome After Coronary Stenting</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators prospectively studied the effect of aspirin on platelet function in 106
      stable outpatients 6 months after successful percutaneous coronary angioplasty. Participants
      were randomized in a double-blind, double-crossover study (80 or 500 mg per day for 6
      months).T
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      Acetylsalicylic acid (aspirin) is widely used in the secondary prevention of coronary artery
      disease. There is controversy regarding the prevalence of aspirin resistance in patients with
      coronary artery disease and the effect of dose on resistance. Our primary aims were to
      determine the degree of platelet responsiveness to aspirin, and to study the influence of
      dose on platelet inhibition and clinical outcomes after coronary stenting.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>laboratory ASA resistance</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>major adverse cardiac events and positive cardiac scan for ischemia</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Coronary Stenting</condition>
  <arm_group>
    <arm_group_label>80 mg ASA dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 months post stent on 80 mg ASA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>500 mg ASA dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 months posr stent on ASA alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>80 mg ASA dosing</intervention_name>
    <arm_group_label>80 mg ASA dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>500 mg ASA dosing</intervention_name>
    <arm_group_label>500 mg ASA dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  6 months post stent without complication

        Exclusion Criteria:

          -  subacute stent thrombosis

          -  unable to discontinue plavix

          -  dont accept to participate

          -  contraindication for ASA use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>67 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>javad kojuri, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Namazi hospital</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <zip>55318</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2009</study_first_submitted>
  <study_first_submitted_qc>August 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2009</study_first_posted>
  <last_update_submitted>August 25, 2009</last_update_submitted>
  <last_update_submitted_qc>August 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Kojuri J</name_title>
    <organization>shiraz University of medical sciences</organization>
  </responsible_party>
  <keyword>ASA resistance</keyword>
  <keyword>coronary stenting</keyword>
  <keyword>platelet function</keyword>
  <keyword>laboratory ASA resistance</keyword>
  <keyword>MACE</keyword>
  <keyword>Positive SPECT</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

